SmartCardia
SmartCardia builds a 7-lead wireless ECG patch and AI-powered cloud platform for continuous cardiac and remote patient monitoring, serving hospitals, cardiology practices, and RPM providers globally with FDA-cleared, CE-marked hardware, SaaS analytics, and US diagnostic services.
- Company typePrivate
- Founded2013
- HeadquartersLausanne, Switzerland
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What SmartCardia does
SmartCardia SA is a Lausanne, Switzerland-based medical technology company founded in 2013 that has developed a cable-free, waterproof 7-lead ECG patch paired with a cloud-based SaaS platform for continuous cardiac and remote patient monitoring. The patch supports 7- or 14-day continuous monitoring with full-disclosure signal transmission (100% of ECG data, not just events) to a cloud platform where SmartNeuralNet, the company's proprietary machine learning engine trained on millions of cardiologist-annotated ECG segments, performs automated arrhythmia detection, predictive patient deterioration alerts, and clinician-facing reporting. A single patch serves multiple service types — Mobile Cardiac Telemetry, Holter, Extended Holter, and Event Monitoring — with a remote 48-hour service-switch capability (Switch 48h) that avoids patient revisits, and a reusable sensor with low-cost disposable patches that lowers per-patient cost.
The company derives revenue from three streams: hardware sales of the reusable sensor and disposable patches, recurring SaaS subscriptions for the cloud analytics and reporting platform, and (in the US) professional diagnostic services billed through insurance via its wholly-owned subsidiary SmartCardia, Inc. (formerly Cardiomedix, Inc., a CMS-enrolled, Joint Commission-accredited IDTF acquired in December 2024). It sells primarily through enterprise field sales targeting hospitals, cardiac centers, and cardiology practices, with regional sales directors covering Europe, the UK, India/Gulf, and the US, and a US VP of Sales leading the post-acquisition commercial push. Regulatory assets include FDA clearance for 14-day continuous monitoring (Sept 2023) and for Mobile Outpatient Cardiac Telemetry (Nov 2024), CE Class IIa approval in Europe, and ISO 13485 and ISO 27001 certifications. The company is led by co-founders Srinivasan Murali (CEO) and Francisco Rincón (CTO), with Dr. Jag Singh (Harvard Medical School, former Mass General Cardiology Clinical Director) as Principal Advisor, and reports 100+ hospital customers, millions of monitored patient hours, and 10+ clinical studies underpinning its positioning, including the SMART-TEL study demonstrating a false-alarm rate of 5 vs 21 (P=.002) versus conventional telemetry.
SmartCardia is venture-backed (approximately $14M Series B in 2023 and a $7.5M Series A in 2018, plus early-stage Venture Kick support and 2024 MedTech Innovator selection) and operates from Lausanne with a US headquarters in Des Plaines, Illinois, and an India office in Mumbai, serving healthcare providers across the cardiac monitoring, electrophysiology, and remote patient monitoring value chain.
SmartCardia firmographics
Firmographics- Name
- SmartCardia
- Legal name
- SmartCardia SA
- Website
- https://smartcardia.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- SmartCardia builds a 7-lead wireless ECG patch and AI-powered cloud platform for continuous cardiac and remote patient monitoring, serving hospitals, cardiology practices, and RPM providers globally with FDA-cleared, CE-marked hardware, SaaS analytics, and US diagnostic services.
- Ownership category
- akta.pro rank
SmartCardia industry classification
Industry- Product category
- Cardiac Monitoring Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders) (HLAHACAB)
- akta.pro secondary industries
- Cardiology Telemedicine Platforms (HLALAGAB), Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI), Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices) (HLACAPAK), Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA)
Keywords
Where SmartCardia is headquartered
LocationHeadquarters
- HQ city
- Lausanne
- HQ country
- Switzerland
- HQ region
- Europe
Offices3 records
Markets served
SmartCardia business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations, Infrastructure
Revenue model
- Medical Device Hardware Sales: Sale of 7-lead ECG patches (reusable sensors and disposable components) to hospitals and healthcare providers. The reusable sensor design with low-cost disposable patches supports recurring revenue from consumables.
- Cloud SaaS Platform: Cloud-based arrhythmia detection, analysis, and reporting platform provided as SaaS to clinicians and healthcare systems. Powers real-time monitoring and automated analysis with SmartNeuralNet AI technology.
- Diagnostic Services (US): US diagnostic services through SmartCardia Inc. (formerly Cardiomedix), an accredited Independent Diagnostic Testing Facility (IDTF). Provides complete cardiac monitoring pathway including MCT and Holter monitoring services, billed through insurance.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
SmartCardia product offering
Product offeringCore offering
SmartCardia manufactures a 7-lead wireless ECG patch and operates a cloud-based SaaS platform (SmartNeuralNet) for AI-powered cardiac arrhythmia detection and remote patient monitoring. The patch is cable-free, waterproof, and supports 7/14 days of continuous monitoring, transmitting 100% of ECG data and vitals (respiration, SpO2, activity) to the cloud in near real time. In the US, the company also operates an accredited Independent Diagnostic Testing Facility (IDTF) to deliver end-to-end cardiac monitoring services.
Differentiator
Problem solved
Functional benefit
Products and services
- SmartCardia 7L Patch with Cloud Platform Cable-free, waterproof wearable 7-lead ECG patch with companion SmartNeuralNet cloud SaaS platform for continuous 7/14-day cardiac and remote patient monitoring. Provides real-time full-disclosure ECG transmission, AI-driven arrhythmia detection, and clinical reporting for hospitals, cardiologists, and electrophysiologists. Single patch serves MCT, Holter, Extended Holter, and Event Monitoring services.
- US Cardiac Diagnostic Monitoring Services (IDTF) Outsourced cardiac diagnostic monitoring services (MCT, Holter, Extended Holter, Event Monitoring) delivered through SmartCardia Inc., a wholly-owned US subsidiary operating as a CMS-enrolled IDTF with Joint Commission accreditation. Billed through in-network coverage with major US insurance providers.
Quantifiable outcome
- False alarms significantly reduced: 5 vs 21 (CCMS) in SMART-TEL clinical study (P = .002)
- +3 more outcomes
Companies that use SmartCardia
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
SmartCardia technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature5 records
SmartCardia partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Cardiomedix, Inc. (acquired and renamed SmartCardia, Inc.)coreSmartCardia completed acquisition of Cardiomedix, Inc., a US Independent Diagnostic Testing Facility (IDTF). The acquisition closes the loop on SmartCardia's US offering, combining its FDA-cleared 7-Lead ECG Patch and AI-driven cloud platform with an accredited US diagnostic facility. Cardiomedix operates under SmartCardia brand as wholly-owned US subsidiary with CMS IDTF enrollment and Joint Commission accreditation, enabling end-to-end cardiac monitoring services in the US market.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
SmartCardia competitors and assessment
Company assessmentBroad incumbents
- Medtronic: Medtronic is a global cardiac device leader with LINQ implantable loop recorders and broader cardiac diagnostics portfolio. Competes at the high-acuity end of cardiac monitoring and adjacent to SmartCardia's patch-based Holter/MCT offerings.
- GE HealthCare: GE HealthCare provides hospital telemetry systems, ECG carts, and patient monitoring infrastructure. Competes with SmartCardia in the inpatient telemetry use case and increasingly in wireless/remote monitoring through MUSE and other digital tools.
- BioTelemetry (Philips): Philips acquired BioTelemetry in 2021, one of the largest US remote cardiac monitoring service providers (MCOT, Holter, Event). Competes with SmartCardia's IDTF channel and offers a broader portfolio including hospital telemetry and sleep diagnostics.
Direct peers
- iRhythm Technologies: iRhythm's Zio is the market-leading wearable ECG patch for ambulatory cardiac monitoring. Direct competitor in 14-day continuous ECG monitoring with AI-driven arrhythmia detection, serving the same cardiology and hospital customer base.
- AliveCor: AliveCor's KardiaMobile and KardiaCloud offer consumer-and-professional ECG monitoring with AI-driven arrhythmia detection. Overlaps with SmartCardia in ECG signal capture and cloud-based analysis, though more skewed toward consumer/ambulatory use cases.
- Preventice Solutions (Boston Scientific): Boston Scientific acquired Preventice (BodyGuardian) in 2022, a direct competitor offering remote cardiac monitoring patches and services (MCT, Event, Holter). Competes head-to-head with SmartCardia in hospital and IDTF channels.
- VitalConnect: VitalConnect provides wearable biosensor patches (Vista) for continuous vital sign and cardiac monitoring in both hospital and remote patient monitoring settings. Direct competitor in patch-based multi-vital monitoring with cloud analytics.
- Bardy Diagnostics (Baxter): Baxter acquired Bardy Diagnostics (CAM patch), a single-lead ECG patch focused on ambulatory monitoring. Competes in the same cardiac monitoring patch category with comparable workflow and reimbursement models.
Emerging players
- Heartbeam: Heartbeam is a smaller public competitor developing 3D ECG signal capture technology for ambulatory cardiac monitoring with AI-driven analysis. Comparable in targeting outpatient telemetry with a differentiated hardware platform.
- Eko Health: Eko offers AI-powered digital stethoscopes and ECG sensing with cloud analytics. Comparable in cloud-based cardiac AI interpretation and clinician workflow, though primarily device-form-factor different.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
SmartCardia social profiles
Digital presenceSmartCardia financial estimates
Financial estimateRevenue estimate
Valuation estimate
SmartCardia leadership team
Management profileNumber of profiles
Profiles9 records
SmartCardia subsidiaries and ownership
Company hierarchySubsidiaries1 record
SmartCardia funding detail
Funding detailFunding overview
Funding rounds5 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SmartCardia M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SmartCardia
What does SmartCardia do?
SmartCardia manufactures a 7-lead wireless ECG patch and operates a cloud-based SaaS platform (SmartNeuralNet) for AI-powered cardiac arrhythmia detection and remote patient monitoring. The patch is cable-free, waterproof, and supports 7/14 days of continuous monitoring, transmitting 100% of ECG data and vitals (respiration, SpO2, activity) to the cloud in near real time. In the US, the company also operates an accredited Independent Diagnostic Testing Facility (IDTF) to deliver end-to-end cardiac monitoring services.
Is SmartCardia a public or private company?
SmartCardia is a private company. It is classified as venture growth investor backed and is currently operating.
When was SmartCardia founded?
SmartCardia was founded in 2013. It employs 11 to 50 people.
Where is SmartCardia based?
SmartCardia is headquartered in Lausanne, Switzerland, in the Europe region.
How does SmartCardia make money?
Three revenue lines are on record. Medical Device Hardware Sales are the primary driver. The others are cloud SaaS Platform and diagnostic Services (US).
Who are SmartCardia's main competitors?
Broad incumbents on record are Medtronic, GE HealthCare and BioTelemetry (Philips). Direct peers are iRhythm Technologies, AliveCor, Preventice Solutions (Boston Scientific), VitalConnect and Bardy Diagnostics (Baxter). Emerging players are Heartbeam and Eko Health.
Does SmartCardia have an API?
No public API is recorded for SmartCardia.
What industry is SmartCardia in?
SmartCardia's product category is Cardiac Monitoring Devices. Its primary akta.pro industry code is HLAHACAB, Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders), with a secondary code of HLALAGAB, Cardiology Telemedicine Platforms. Its NAICS code is 334510 and its SIC code is 3845.